Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 208

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 208
---
 our CEO’s fiscal 2022 compensation was revised by reducing his equity award and re-formulating the equity award to consist 60% of performance-based RSUs and 40% of time-based RSUs. The CEO's Stock Awards are described in more detail in the "Our CEO’s Fiscal 2022 Equity Award" section in our 2023 proxy statement. The amounts reported for Christopher Anzalone in the Stock Awards column reflect the grant date fair value of a July 2022 RSU award that is subject to vesting upon the achievement of specific performance conditions, as described in the Compensation Discussion and Analysis section in our 2023 proxy statement. We determined the performance conditions that were probable and not probable of being achieved as of the grant date, as defined under applicable accounting guidance, and assigned a grant date fair value of $6,229,538 based on this evaluation. The amounts reported in the Summary Compensation Table for these awards may not represent the amounts that Christopher Anzalone will realize from the awards. Whether, and to what extent, an NEO realizes value will depend on our actual operating performance, stock price fluctuations and the NEO’s continued employment. (8) Dr. San Martin left the Company on February 1, 2024 and Ms. Oliver served as the Company's Chief Commercial Officer until October 2024. Table of Contents 2025 PROXY STATEMENT Executive Compensation 45

Fiscal 2024 Grants of Plan Based Awards Table The following table sets forth cash bonus and equity grants made to the NEOs in fiscal 2024: Estimated Future Payouts Under Non-Equity Incentive Plan Awards (1) Estimated Future Payouts Under Equity Incentive Plan Awards (2) All Other Stock Awards: Number of Shares of Stock or Units (#) (3) Grant Date Fair ValueName Grant Date Target ($) Maximum ($) Target (#) Christopher Anzalone Cash Bonus $960,000 $1,440,000 — — — PRSUs 12/22/2023 — 340,000 — $10,319,000 Kenneth Myszkowski Cash Bonus $262,080 — — — RSUs 01/04/2024 — — 75,000 $2,589,750 Patrick O’Brien Cash Bonus $270,000 — — — RSUs 01/04/2024 — — 85,000 $2,935,050 James Hamilton Cash Bonus $262,080 — — — RSUs 01/04/2024 —